In a woman undergoing cervical screening whose Aptima high‑risk human papillomavirus (HPV) test is negative for intraepithelial lesion or malignancy, endometrial cells are identified, and the vaginal flora shows a predominance of cocco‑bacilli consistent with bacterial vaginosis, what is the clinical significance and recommended management?

Management of Negative HPV Test with Endometrial Cells and Bacterial Vaginosis

This patient requires routine cervical cancer screening follow-up in 3 years (or per her age-specific interval), evaluation of the endometrial cells based on her age and menstrual status, and treatment of bacterial vaginosis only if symptomatic. 1, 2

Cervical Cancer Screening Management

The negative HPV test result is the key finding that determines cervical screening management. When the Aptima HPV test is negative for intraepithelial lesion or malignancy, the patient has a very low risk of high-grade cervical disease, with a negative predictive value approaching 99.7–100% for CIN 3+ over the next two years. 2, 3

Follow-up Interval Based on Age

• For women aged 21–29 years: Return to routine screening with repeat cytology in 12 months if this was part of ASC-US triage, or continue routine screening every 3 years with cytology alone. 1, 2

• For women aged 30–65 years: Return to routine co-testing (Pap + HPV) in 3 years if co-testing is available, or Pap testing alone every 3 years if co-testing is not performed. 1, 2

• The presence of endometrial cells or bacterial vaginosis does not alter the cervical cancer screening interval, as these findings are unrelated to cervical pathology and do not increase cervical cancer risk. 2

Aptima HPV Test Performance

The Aptima HPV assay detects E6/E7 mRNA from 14 high-risk HPV types and demonstrates excellent clinical performance, with sensitivity of 91–98% and specificity of 53–75% for detecting CIN 2+ lesions. 3, 4 This mRNA-based test has higher specificity than DNA-based HPV tests while maintaining similar sensitivity. 3, 4

Management of Endometrial Cells

The clinical significance of endometrial cells depends entirely on the patient's age and menstrual status:

Premenopausal Women

• In premenopausal women during the first half of the menstrual cycle (days 1–12), benign endometrial cells are a normal finding and require no additional evaluation. 2

• If the patient is in the second half of her cycle (day 13 or later) or if menstrual timing is unknown, clinical correlation is needed. 2

Women ≥35 Years or Postmenopausal

• For women aged ≥35 years with endometrial cells present on Pap smear, endometrial sampling (endometrial biopsy) should be performed to exclude endometrial hyperplasia or carcinoma, regardless of menstrual timing. 1

• For postmenopausal women, the presence of any endometrial cells is abnormal and mandates endometrial sampling. 1

Key Distinction

The endometrial cells finding is completely independent of the cervical screening result and does not modify cervical cancer screening management. 2 Each abnormality must be addressed according to its respective guideline. 2

Management of Bacterial Vaginosis

The predominance of coccobacilli consistent with bacterial vaginosis (BV) on Pap smear is an incidental finding that requires treatment only if the patient is symptomatic.

Treatment Indications

• Symptomatic BV (vaginal discharge, odor, irritation) should be treated with standard antibiotic therapy. 1

• Asymptomatic BV detected incidentally on Pap smear does not require treatment in non-pregnant women. 1

Clinical Context of BV and HPV

While research suggests that BV may be associated with increased risk of HPV persistence and progression to high-grade lesions when co-infection occurs, this patient's negative HPV test indicates she does not have active high-risk HPV infection. 5, 6

• Studies show that co-infection of BV with high-risk HPV increases risk for high-grade squamous intraepithelial lesions, with Gardnerella vaginalis being the most common BV organism (33.8% prevalence). 5

• However, in the absence of HPV infection, BV alone does not increase cervical cancer risk or alter screening recommendations. 5, 6

• The enrichment of Lactobacillus iners under HPV infection may contribute to vaginal dysbiosis, but this is not relevant when HPV testing is negative. 6

Common Pitfalls to Avoid

• Do not perform repeat HPV testing before the recommended screening interval (3 years for most women aged 30–65, or 12 months for specific triage scenarios), as earlier testing increases false-positive rates without improving disease detection. 1, 2

• Do not refer for colposcopy based on the presence of endometrial cells or bacterial vaginosis when cervical cytology and HPV testing are negative, as these findings do not indicate cervical pathology. 2

• Do not treat asymptomatic bacterial vaginosis detected incidentally on Pap smear, as treatment is indicated only for symptomatic patients or specific high-risk situations (e.g., pregnancy, prior preterm birth). 1

• Do not conflate endometrial pathology with cervical cancer screening—these are separate organ systems requiring independent evaluation. 2

Immediate Action Steps

1. Schedule routine cervical cancer screening according to the patient's age-specific interval (typically 3 years for women 30–65 with co-testing, or per prior screening history). 1, 2

2. Evaluate endometrial cells based on patient age:

   • If premenopausal and in first half of cycle: reassure patient, no action needed. 2
   • If ≥35 years or postmenopausal: perform endometrial biopsy. 1

3. Assess for BV symptoms (discharge, odor, irritation):

   • If symptomatic: treat with standard BV therapy. 1
   • If asymptomatic: no treatment needed. 1

4. Counsel the patient that her negative HPV test indicates very low risk of cervical disease and that the other findings do not affect her cervical cancer screening schedule. 2, 3